A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically. The Mel-Ipi-Rx phase 1 study aimed to determine the maximum tolerated dose (MTD) and safety profile of radiotherapy combined with ipilimumab in patients with metastatic melanoma. A 3+3 dose escalation design was …
Continua a leggere

Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma

Melanoma can be classified based on the detection of relevant oncogenic driver mutations. These mutations partially determine a patient’s treatment options. MEK inhibitors have demonstrated little efficacy in patients with NRAS-mutated melanoma owing to primary and secondary resistance. We report two patients with NRAS-mutant metastatic melanoma with long-term response to …
Continua a leggere

Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs)

Severe Cutaneous Adverse Reactions (SCARs) [Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Drug Rash with Eosinophilia and Systemic Syndrome (DRESS), Acute Generalized Exanthematous Pustulosis (AGEP), and Generalized Bullous Fixed Eruption (GBFE)] are severe drug reactions that often require hospitalization and could be fatal. BRAF and …
Continua a leggere

Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data

Identifying patients with sentinel node (SN)-negative melanoma who are at greatest risk of recurrence is important. The European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group proposed a prognostic model that has not been validated in population-based data. The EORTC nomogram includes Breslow thickness, ulceration status and anatomical location …
Continua a leggere

Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma

Combination treatments targeting the MEK-ERK pathway and checkpoint inhibitors have improved overall survival in melanoma. Resistance to treatment especially in the brain remains challenging, and rare disease subtypes such as acral melanoma are not typically included in trials. Here we present analyses from longitudinal sampling of a patient with metastatic acral melanoma that …
Continua a leggere